Comparison of Immunohistochemical and Biochemical Assay of Steroid Receptors in Primary Breast Cancer: Clinical Associations and Reasons for Discrepancies

Acta Oncologica

Volumn 42, Issue 7, 2003, Pages 719-725

  Chebil, Gunilla ^a   Bendahl, Pär Ola ^b   Idvall, Ingrid ^a   Fernö, Mårten ^b  

^a HELSINGBORG HOSPITAL   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOASSAY; CELLS; CYTOLOGY; DISEASES; HISTOLOGY; IMMUNOLOGY; ONCOLOGY;

NON-INVASIVE CELLS; SCLEROSIS;

TUMORS;

ESTROGEN RECEPTOR; PARAFFIN; PROGESTERONE RECEPTOR; STEROID RECEPTOR; TAMOXIFEN;

ANALYTIC METHOD; ARTICLE; ARTIFACT; BIOASSAY; BREAST CANCER; CANCER SURVIVAL; CANCER TISSUE; CONTROLLED STUDY; CYTOSOL; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NECROSIS; PRIORITY JOURNAL; SCLEROSIS;

BREAST NEOPLASMS; CYTOSOL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASMS, HORMONE-DEPENDENT; PARAFFIN EMBEDDING; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SURVIVAL RATE; TAMOXIFEN;

EID: 0345017801     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/02841860310004724     Document Type: Article

References (23)

1. McGuire WL. An update on estrogen and progesterone receptors in prognosis for primary and advanced breast cancer. In: Iacobelli S, et al, eds. Hormones and Cancer. New York: Raven Press; 1980. p. 337-43.
2. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998; 351: 1451-1467.
3. Rydén S, Fernö M, Borg Å, et al. Prognostic significance of estrogen and progesterone receptors in stage II breast cancer. J Surg Oncol 1988; 37: 221-6.
4. Raemaekers JM, Beex LV, Pieters GF, et al. Progesterone receptor activity and the response to the first endocrine therapy in advanced breast cancer. Eur J Cancer Clin Oncol 1987; 23: 443-8.
5. Ravdin PM, Green S, Dorr TM, et al. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 1992; 10: 1484-91.
6. Fernö M, Stål O, Baldetorp B, et al. South Sweden Breast Cancer Group and South-East Sweden Breast Cancer Group. Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels. Breast Cancer Res Treat 2000; 59: 69-76.
7. Battifora H, Mehta P, Ahn C, Esteban JM. Estrogen receptor immunohistochemical assay in paraffin-embedded tissue. A better gold standard? Appl Immunohistochem 1993; 1: 39-45.
8. Esteban JE, Kandalaft PL, Mehta P, et al. Improvement of the quantification of estrogen and progesterone receptors in paraffin-embedded tumors by image analysis. Am J Clin Pathol 1993; 99: 32-8.
9. Alberts SR, Ingle JN, Roche PR, et al. Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 1996; 78: 764-72.
10. Barnes DM, Harris WH, Smith P, et al. Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer 1996; 74: 1445-51.
11. Fernö M, Andersson C, Fallenius G, Idvall I, for the South Sweden Breast Cancer Group. Oestrogen receptor analysis of paraffin sections and cytosol samples of primary breast cancer in relation to outcome after adjuvant tamoxifen treatment. Acta Oncol 1996; 35: 17-22.
12. Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-81.
13. Zafrani B, Aubriot M-H, Mouret E, et al. High sensitivity and specificity of immunohistochemistry for the detection of hormone receptors in breast carcinoma: comparison with biochemical determination in a prospective study of 793 cases. Histopathol 2000; 37: 536-45.
14. Pertschuk LP, Feldman JG, Kim Y-D, et al. Estrogen receptor immunocytochemistry in paraffin embedded tissues with ER1D5 predicts breast cancer endocrine response more accurately than H222Spγ in frozen sections or cytosol-based ligand-binding assays. Cancer 1996; 77: 2514-9.
15. Blomqvist C, von Boguslawski K, Stenman U-H, et al. Long-term prognostic impact of immunohistochemical estrogen receptor determinations compared with biochemical receptor determination in primary breast cancer. Acta Oncol 1997; 36: 530-2.
16. Goldhirsch A, Glick JH, Gelber RD, Senn H-J. Meeting highlights: International consensus panel on the treatment of primary breast cancer. J Natl Cancer Inst 1998; 90: 1601-8.
17. Altman DG. Practical statistics for medical research. London, UK: Chapman & Hall; 1991.
18. StataCorp. 2001. Stata Statistical Software: Release 7.0. College Station, TX: Stata Corporation.
19. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika 1982; 69: 239-41.
20. Pichon MF, Broet P, Magdalenat H, et al. Prognostic value of steroid receptors after long-term follow-up of 2257 operable breast cancers. Br J Cancer 1996; 73: 1545-51.
21. Hilsenbeck SG, Ravdin PM, de Moor CA, et al. Time-dependence of hazard ratios for prognostic factors in primary breast cancer. Breast Cancer Res Treat 1998; 52: 227-37.
22. Clark G. Prognostic and predictive factors. In: Harris J, Lippman M, Morrow M, Hellman S, eds. Diseases of the breast. Philadelphia: Lippincott-Raven; 1996. p. 461-85.
23. Kuukasjärvi T, Kononen J, Helin H, et al. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996; 14: 2584-9.